• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Oyster point

Quote
anonymous said:
Hopefully now, starting with has been old dead weight JS
He’s clueless
No track record of success at Shire/Takeda/Novartis

A product of fortunate timing with Lucentis…anyone could’ve claimed done well at that time,

he’s been downhill ever since

time to cut the dead weight. We are tired of hearing about his “experience at Genentech and with Lucentis”
It is irrelevant
Read the room Snisarenko
We don’t care because it doesn’t matter
Click to expand...

looks like Snisarenko owns you. He’s in your head. Hahahahahaha
 
































anonymous said:
Never…..

The Shire Leadership does not know how to tell the truth

Only terrorize and torture the sales force

get out while you can….
Click to expand...

Terrorize and toture how? We are a startup, there isn’t another option other than performance. If you want to stay off the radar and perform at the bottom third, go to Novartis
 




anonymous said:
Terrorize and toture how? We are a startup, there isn’t another option other than performance. If you want to stay off the radar and perform at the bottom third, go to Novartis
Click to expand...

How about cut out the funds for useless spending (useless dbls and excessive ,repetitive marketing) and release a commercial ?? You’re doing the same thing and it’s not working ... time to switch gears .
 
























Feeling good about the changes…it can only get better. cutting the unnecessary costs with JS makes us better as a team and better with our customers. I’m happy I won’t have to feel nervous about him meeting with my customers or being associated with his inappropriateness with me, the customers and even my boss.
 




















Top Bottom
Back
Quote